Sung-Chuan Chao

Sung-Chuan Chao

Auto-generated profile, based on publicly available information

Sung-Chuan Chao

Department of Traumatology, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei, 100225, Taiwan, 886 2-23123456, 886 2-23825540

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SCSung-Chuan Chao
Sung-Chuan Chao
YCYing-Ju Chen
Ying-Ju Chen
KHKuo-How Huang
Kuo-How Huang
KKKuan-Lin Kuo
Kuan-Lin Kuo
TYTing-Hua Yang
Ting-Hua Yang
SLShing-Hwa Liu
Shing-Hwa Liu
Chondrosarcoma is a malignant primary bone tumor. Sirtuin-1 (SIRT1), which is a member of sirtuin family, plays a dual role either in cancer promotion or suppression. There is no report about the role of SIRT1 in the human chondrosarcoma cells. Resveratrol is a potent activator of SIRT1. However, its effects on chondrosarcoma have not been extensively studied. Here, we investigated the role of SIRT1 induction by resveratrol in human chondrosarcoma cell growth and tumor progression. Resveratrol significantly decreased cell viability and induced cell apoptosis in human chondrosarcoma cells in a dose-dependent manner. The protein expression and activity of SIRT1 were activated after treatment with resveratrol. Resveratrol significantly inhibited NF-κB signaling by deacetylating the p65 subunit of NF-κB complex, which could be reversed by siRNA-SIRT1 transfection or deacetylation inhibitor MS-275. Resveratrol induced-apoptosis involved a caspase-3-mediated mechanism. Both siRNA-SIRT1 transfection and MS-275 significantly inhibited the resveratrol-induced caspase-3 cleavage and activity in human chondrosarcoma cells. Moreover, in vivo chondrosarcoma xenograft study revealed a dramatic reduction in tumor volume and the increased SIRT1 and cleaved caspase-3 expressions in tumors by resveratrol treatment. These results suggest that resveratrol induces chondrosarcoma cell apoptosis via a SIRT1-activated NF-κB deacetylation and exhibits anti-chondrosarcoma activity in vivo.

13 June 2025 in Archives of Plastic Surgery
Verified
Journal Article
Open access
PDF file
QXQingping Xie
Qingping Xie
CPChangsik John Pak
Changsik John Pak
JKJin Geun Kwon
Jin Geun Kwon
SCSung-Chuan Sungchuan Chao Chao
Sung-Chuan Sungchuan Chao Chao
JHJoon Pio Hong
Joon Pio Hong
This case report explores the therapeutic potential of lymphovenous bypass (LVB) surgery performed at the neck in neurodegenerative diseases, specifically Alzheimer's disease (AD) dementia. The subject is a 58-year-old woman who was previously healthy but began experiencing unexplained memory decline and frequent disorientation in the past 7 years, leading to an AD diagnosis. Despite ongoing pharmaceutical therapy, her symptoms progressed to severe dementia accompanied by behavioral and psychological symptoms of dementia (BPSD). Her Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores were both 0/30, and 18F-AV-45 PET/CT revealed abnormal brain amyloid load. For salvage therapy, she underwent LVBs on her neck bilaterally. Postoperatively, she got better MMSE and MoCA scores with dramatic improvement in communication and activity. 18F-AV-45 PET/CT scans 4 months after surgery indicated a reduction in abnormal brain amyloid deposits. This case report highlights the potential effectiveness of LVB surgery in reducing brain amyloid load and attenuating cognitive impairment and BPSD. Further research with animal experiments and clinical trials is necessary to confirm these findings.

20 October 2026 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
SCSung-Chuan Chao
Sung-Chuan Chao
WLWei-Hsin Lin
Wei-Hsin Lin
SLShing-Hwa Liu
Shing-Hwa Liu
RYRong-Sen Yang
Rong-Sen Yang
While Western literature identifies age, histological grade, tumor characteristics, and metastasis as key prognostic factors for chondrosarcoma survival, data specifically focusing on the Taiwanese population remain sparse. This retrospective study included patients who were pathologically diagnosed with chondrosarcoma between January 1998 and July 2016. Clinical and demographic variables were collected, including sex, age, tumor characteristics (size, anatomical location, histological subtype, and pathological grade), treatment modalities (surgical approach and adjuvant therapies), and disease status within a five-year interval following diagnosis. Cox proportional hazards and logistic regression models were utilized to evaluate prognostic factors and to construct a predictive model. Among 58 patients (mean age 47.4 ± 18.3 years; 5-year OS 77.6%), multivariate Cox regression showed that advanced age, progressive systemic disease (aHR 10.07, 95% CI: 1.49-68.00; p < 0.05), and primary metastatic disease (aHR 11.03, 95% CI: 1.62-75.20; p < 0.05) independently predicted worse survival. The multivariate logistic regression model demonstrated high discriminative ability (AUC = 0.954), supporting the use of the derived nomogram for individualized prognosis. This study identifies advanced age and unfavorable disease status as independent negative predictors of 5-year survival in chondrosarcoma. The developed prognostic model and nomogram demonstrated high predictive accuracy, providing a robust tool for clinical risk stratification and personalized management of this patient population.

24 November 2021 in Emergency Medicine Journal
Verified
Journal Article
Closed access
PDF file
TLTsae-Ni Lee
Tsae-Ni Lee
CCCho-Han Chiang
Cho-Han Chiang
SCSung-Chuan Chao
Sung-Chuan Chao

8 June 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
HLHsin-Ying Lee
Hsin-Ying Lee
CWChi-Chuan Wang
Chi-Chuan Wang
TCTien-Jyun Chang
Tien-Jyun Chang
CCChi-Chao Chao
Chi-Chao Chao
SHSung-Tsang Hsieh
Sung-Tsang Hsieh
SCSung-Chuan Chao
Sung-Chuan Chao
Background: Diabetic peripheral neuropathy (DPN) is a length-dependent, symmetric sensorimotor polyneuropathy with a substantial global and regional burden. Current pharmacologic options are largely symptomatic and do not modify the disease. Lymphovenous bypass (LVB), a supermicrosurgical procedure established for lymphedema, may modulate lymphatic-immune-microvascular dysfunction relevant to DPN. Objective: The primary objective is to determine whether LVB combined with standard of care (SOC) improves small-fiber and autonomic function compared with SOC alone at 6 months. Secondary objectives are to evaluate the effects of LVB on large-fiber function, neuropathic pain, ulcer healing, quality of life, and relevant biomarkers, as well as to characterize the safety profile of LVB. Methods: This is a SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials)–aligned, single-center, randomized, controlled, parallel-group superiority trial with a 2:1 allocation (LVB+SOC vs SOC alone). Randomization is stratified based on the presence or absence of active diabetic foot ulcers, as defined by the International Working Group on the Diabetic Foot and Infectious Diseases Society of America criteria. In total, 60 adults aged 20 to 80 years with confirmed DPN will be enrolled. LVB involves lymphatic-venous anastomosis to venules ≤0.8 mm. SOC consists of guideline-based glycemic and risk-factor management, pain control, and standardized wound care. Outcome assessors and statisticians are blinded. The primary outcomes are changes in clinical neuropathy burden and pain severity at 6 and 12 months. Secondary outcomes comprise objective measures of somatic and autonomic physiology, histopathological nerve fiber density, biological serum markers, and longitudinal ulcer epithelialization parameters. Data analysis will use mixed-effects models for repeated measures, with a sample size of 60 adults providing 80% power to detect a conservative between-group effect size of Cohen d =0.70. Results: Recruitment commenced in February 2026 and is planned to continue through July 31, 2027, with follow-up through July 31, 2028. As of May 2026, we have enrolled 3 participants. The first participant has been treated, and a second participant is scheduled to undergo treatment. Data analysis and reporting are anticipated between late 2027 and early 2028. No outcome data are included. Conclusions: This trial tests a mechanism-based, nonpharmacologic adjunct targeting lymphatic-immune-microvascular dysfunction in DPN. If effective, LVB could inform phenotype-directed treatment algorithms and motivate multicenter evaluation and health economic analyses.

18 May 2013 in Formosan Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SCSung-Chuan Chao
Sung-Chuan Chao
HCHsiung-Fei Chien
Hsiung-Fei Chien
YKYuan-Sung Kuo
Yuan-Sung Kuo
Failure of fusion of auricular components is the probable cause of cleft ear. Many surgical techniques such as Z-plasties and local flap surgeries have been proposed for the reconstruction of an earlobe cleft. We reported an innovative and simple method for the reconstruction of a congenital earlobe cleft by elevating a random postauricular flap based on the dermal pedicle at the indentation of the cleft under local anesthesia. The flap was folded inward along the diagonal line to repair the defect and then was closed primarily along the margin of the cleft after deepithelialization. During the postoperative course, there was neither cyanotic change nor flap partial loss. The donor site was closed primarily, with a good aesthetic result. The auricle shape remained well at the 4-year follow-up. Therefore we suggest this procedure as an alternative choice for the reconstruction of a congenital earlobe cleft with a large defect.